Journal
ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 9
Volume 9, Issue -, Pages 649-674Publisher
ANNUAL REVIEWS
DOI: 10.1146/annurev-clinpsy-050212-185549
Keywords
nicotine; screening; smoke-free policies; nAChR; varenicline; mecamylamine
Categories
Funding
- National Institutes of Health [P50DA033945, R21AA018273, R01AA017976, RL1DA024857, R03DA027052]
- Women's Health Research at Yale
- Yale Cancer Center
- State of Connecticut, Department of Mental Health and Addiction Services
- NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA018273, R01AA017976] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DRUG ABUSE [R03DA027052, RL1DA024857, P50DA033945] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Currently, 8.5% of the US population meets criteria for alcohol use disorders, with a total cost to the US economy estimated at $234 billion per year. Alcohol and tobacco use share a high degree of comorbidity and interact across many levels of analysis. This review begins by highlighting alcohol and tobacco comorbidity and presenting evidence that tobacco increases the risk for alcohol misuse and likely has a causal role in this relationship. We then discuss how knowledge of alcohol and tobacco interactions can be used to reduce alcohol use, focusing on whether (a) smoking status can be used as a clinical indicator for alcohol misuse, (b) tobacco policies reduce alcohol use, and (c) nicotinic-based medications can be used to treat alcohol use disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
